- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02932904
Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers
A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is called vortioxetine. This study will look at the effect of treatment on sexual functioning in healthy participants.
The study will enroll approximately 352 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):
- Vortioxetine 10 mg
- Vortioxetine 20 mg
- Paroxetine 20 mg
- Placebo (dummy inactive pill) - this is a capsule that looks like the study drug but has no active ingredient
All participants will be asked to take one tablet/capsule, daily, orally for up to 5 weeks.
This multicenter trial will be conducted in United States. The overall time to participate in this study is approximately 7 weeks. Participants will be contacted by telephone 2 weeks after last dose of study drug for a follow-up assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Encino, California, United States
-
Long Beach, California, United States
-
Torrance, California, United States
-
-
Florida
-
Jacksonville, Florida, United States
-
Orlando, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Decatur, Georgia, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Nevada
-
Las Vegas, Nevada, United States
-
-
Oregon
-
Portland, Oregon, United States
-
-
Texas
-
Austin, Texas, United States
-
Dallas, Texas, United States
-
San Antonio, Texas, United States
-
-
Virginia
-
Charlottesville, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Is sexually active and has been in a steady relationship and plans to remain in that relationship for the duration of the study.
- Has a body mass index (BMI) of 18 to 35 kg/m^2, inclusive, at the Screening and Baseline Visits.
- If female, has a regular menstrual cycle.
- Has normal sexual functioning, as defined by a Changes in Sexual Functioning Questionnaire (CSFQ-14) total score >47 (men) or >41 (women) at the Screening and Baseline Visits.
- If females, taking allowed hormonal contraceptives is on a stable dose for ≥3 months prior to the Baseline Visit and continues on the stable dose for the duration of the study.
Exclusion Criteria:
- Has received vortioxetine and/or paroxetine in a previous clinical study or as a therapeutic agent.
- Is positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or human immunodeficiency virus (HIV) at the Screening Visit or has any known sexually transmitted diseases.
- Has glycosylated hemoglobin (HbA1c) ≥7% at the Screening Visit.
- Has a clinically significant abnormal electrocardiogram (ECG) at the Screening Visit.
- Has a known history of or currently has increased intraocular pressure or is at risk of acute narrow-angle glaucoma.
- Has a history of depression or any other psychiatric illness.
- Has a significant risk of suicide according to the investigator's clinical judgment, or has made a suicide attempt in the previous 6 months.
- Has current sexual dysfunction, or a history of a diagnosis or treatment of sexual dysfunction.
- Has had a surgical or medical procedure on reproductive/genitourinary organs (excluding uncomplicated vasectomy and tubal ligation).
- If female, has polycystic ovarian syndrome.
- Has hypogonadism or has a free testosterone value outside the normal range at the Screening Visit that is indicative of hypogonadism.
- Has a thyroid-stimulating hormone (TSH) value outside the normal range at the Screening Visit that is deemed clinically significant by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vortioxetine 10 mg
Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
|
Vortioxetine Overencapsulated Tablet
|
Experimental: Vortioxetine 20 mg
Vortioxetine 10 mg, overencapsulated tablets, orally, once daily for up to 1 week followed by vortioxetine 20 mg, overencapsulated tablets, orally, once daily from Week 2, up to 4 weeks.
|
Vortioxetine Overencapsulated Tablet
|
Active Comparator: Paroxetine 20 mg
Paroxetine 20 mg, overencapsulated tablets, orally, once daily for up to 5 weeks.
|
Paroxetine Overencapsulated Tablets.
|
Placebo Comparator: Placebo
Vortioxetine placebo matching-capsules, orally, once daily for up to 5 weeks.
|
Vortioxetine Placebo-matching Capsules.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Full Analysis Set (FAS)
Time Frame: Baseline and Week 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70.
Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Week 5
|
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 1 (mFAS1)
Time Frame: Baseline and Week 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70.
Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Week 5
|
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Week 5 in Modified Full Analysis Set 2 (mFAS2)
Time Frame: Baseline and Week 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70.
Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Week 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in the CSFQ-14 Total Score Difference for Vortioxetine Versus Paroxetine at Weeks 1, 2, 3 and 4
Time Frame: Baseline and Weeks 1, 2, 3 and 4
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70.
Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Weeks 1, 2, 3 and 4
|
Change From Baseline in CSFQ-14 Total Score Difference for Paroxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
Time Frame: Baseline and Weeks 1, 2, 3, 4 and 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70.
Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Weeks 1, 2, 3, 4 and 5
|
Change From Baseline in CSFQ-14 Total Score Difference for Vortioxetine Versus Placebo at Weeks 1, 2, 3, 4 and 5
Time Frame: Baseline and Weeks 1, 2, 3, 4 and 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning as a total score (14 items) and on the subscales of pleasure (1 item), desire/frequency (2 items), desire/interest (3 items), arousal (3 items), orgasm (3 items) and 2 additional items are included in the total score, but do not map to a specific phase of the sexual response cycle, rated on a 5-point scale from 1 to 5 with a total score range from 14 to 70.
Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Weeks 1, 2, 3, 4 and 5
|
Percentage of Participants Meeting Criteria for Sexual Dysfunction at Weeks 1, 2, 3, 4 and 5
Time Frame: Weeks 1, 2, 3, 4 and 5
|
Sexual dysfunction is defined as CSFQ-14 score ≤47 for men and ≤41 for women.
|
Weeks 1, 2, 3, 4 and 5
|
Change From Baseline in CSFQ-14 Subscales 5 Dimensions at Weeks 1, 2, 3, 4 and 5
Time Frame: Baseline and Weeks 1, 2, 3, 4 and 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the subscales of pleasure (1 item, score range 1-5), desire/frequency (2 items, score range 2-10), desire/interest (3 items, score range 3-15), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Weeks 1, 2, 3, 4 and 5
|
Change From Baseline in CSFQ-14 3 Phases of the Sexual Response Cycle (Desire, Arousal, and Orgasm/Completion) at Weeks 1, 2, 3, 4 and 5
Time Frame: Baseline and Weeks 1, 2, 3, 4 and 5
|
The CSFQ-14 is a structured, self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning consisting of 14 items that measure sexual functioning on the 3 phases of the sexual response cycle , desire (5 items, score range 5-25), arousal (3 items, score range 3-15), and orgasm (3 items, score range 3-15), rated on a 5-point scale from 1 to 5. Higher scores reflect higher sexual functioning.
A negative change from baseline indicates that symptoms have worsened.
|
Baseline and Weeks 1, 2, 3, 4 and 5
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Serotonin 5-HT1 Receptor Agonists
- Serotonin Receptor Agonists
- Serotonin Antagonists
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Serotonin 5-HT3 Receptor Antagonists
- Paroxetine
- Vortioxetine
Other Study ID Numbers
- Vortioxetine-4001
- U1111-1174-1779 (Other Identifier: WHO)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Vortioxetine
-
H. Lundbeck A/SCompleted
-
H. Lundbeck A/SCompletedPharmacokineticsChina
-
H. Lundbeck A/SCompleted
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedSingle Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating TabletsMajor Depressive Disorder (MDD)India
-
H. Lundbeck A/STakedaCompletedDepressive Disorder, MajorFinland, Estonia
-
H. Lundbeck A/SCompletedAttention Deficit Hyperactivity DisorderUnited States
-
H. Lundbeck A/SCompletedMajor Depressive DisorderBulgaria, Estonia, Latvia
-
H. Lundbeck A/SCompleted
-
Rush University Medical CenterElMindA Ltd; Takeda Pharmaceuticals North America, Inc.CompletedMajor Depressive DisorderUnited States